安络化纤丸治疗HBeAg阴性乙型肝炎肝硬化的临床观察

目的 观察安络化纤丸治疗HBeAg阴性乙型肝炎(乙肝)肝硬化(LC)患者的疗效.方法 随机将68例HBeAg阴性乙肝肝硬化患者分为治疗组38例、对照组30例,治疗组给予口服安络化纤丸,每次6 g、3/d;对照组给予护肝片,每次4片、3/d,疗程均为3个月.观察治疗前后临床症状、体征的变化以及肝脾影像学改变;肝功能、肝纤维化、病毒学指标的变化和药物的不良反应.结果 安络化纤丸临床使用安全、可靠;在肝功能改善、症状缓解,有一定效果;治疗组与对照组比较,脾厚测量平均值明显缩小,肝纤维化指标HA和Ⅳ-C明显下降,LN无明显改变.结论 安络化纤丸治疗HBeAg阴性乙肝肝硬化临床应用安全可靠,在保肝、脾脏回缩、抗纤维化方面具有一定疗效.     

安络化纤丸治疗乙型肝炎肝硬化疗效观察

目的探讨安络化纤丸治疗代偿期乙型肝炎肝硬化的临床疗效及安全性。方法选择代偿期乙型肝炎肝硬化患者78例,治疗组(46例)口服安络化纤丸和拉米夫定6个月,观察其血清肝纤维化指标、肝功能生化指标变化及不良反应,并与对照组(32例,单用拉米夫定)进行比较。结果治疗组肝纤维化指标和肝功能生化指标均优于对照组,有显著差异(P<0.05)。结论安络化纤丸具有抗肝纤维化和改善肝功能作用,治疗代偿期乙型肝炎肝硬化临床疗效较好,安全性好。     

安络化纤丸治疗慢性乙型肝炎肝纤维化的疗效观察

目的评价安络化纤丸治疗慢性乙型肝炎肝纤维化的有效性及安全性。方法采用随机开放性临床实验设计。选用慢性乙型肝炎肝纤维化患者72例,随机分配到实验组37例(安络化纤丸每次6克,口服,每天两次,疗程6个月),对照组35例(常规保肝组,疗程6个月)。治疗前后检测肝肾功能、肝纤维化指标(HA、LN、PC-Ⅲ、Ⅳ-C)、血常规、B超。结果实验组血清肝纤维化指标改善优于对照组(P0.05),实验组治疗后门脉主干内径及脾脏厚度较治疗前有明显缩小(P0.05)。结论安络化纤丸具有明显的抗肝纤维化作用,是治疗慢性乙型肝炎肝纤维化的非常有效和安全的药物。     

安络化纤丸对慢性乙型肝炎和肝硬化患者血清肝纤维化指标的影响

目的观察安络化纤丸对肝血清纤维化指标的影响。方法随机将83例慢性乙型肝炎、肝炎肝硬化患者分为治疗组和对照组。治疗组在常规护肝治疗基础上加用安络化纤丸治疗，对照组仅行常规护肝治疗，分别于3个月、6个月时观察两组血清肝纤维化指标的变化。结果治疗结束时治疗组患者血清肝纤维化指标明显下降，部分恢复正常，治疗前后对比有显著性差异，对照组血清肝纤维化指标无明显变化，治疗前后对比无明显差异。结论安络化纤丸对慢性乙型肝炎、肝炎肝硬化患者血清肝纤维化指标有降低作用，提示安络化纤丸有抗肝纤维化作用，值得临床进一步研究。     

安络化纤丸治疗乙型肝炎后早期肝硬化的临床观察

1临床资料 观察安络化纤丸治疗乙型肝炎后早期肝硬化的临床疗效,寻找治疗肝纤维化的有效方法.同期抽样,相同病情,年龄、性别,检测指标相仿的57例乙型肝炎后早期肝硬化的患者,诊断符合2000年9月第10次全国病毒性肝炎防治方案[1].随机分成2组.治疗组28例患者服用安络化纤丸,剂量6g/次,3/d.对照组29例患者服用常规保肝药,疗程均为3～6个月.结果显示安络化纤丸可有效改善患者的临床表现,有明显抗肝纤维化作用,治疗后HA、LN、PC-Ⅲ、Ⅳ-C均有明显下降,2组比较有显著差异(P＜0.05),见表1.     

核苷类似物联合安络化纤丸治疗乙型肝炎肝硬化30例

目的：通过瞬时弹力成像系统（ FibroScan ）,以及其他辅助检查观察慢性乙型肝炎肝硬化患者应用核苷类似物联合安络化纤丸的治疗效果。方法：60例乙型肝炎肝硬化患者,分为治疗组和对照组,每组30例。治疗组患者口服核苷类似物及安络化纤丸,对照组患者口服核苷类似物及护肝片,两组患者疗程均为6个月。结果：所有患者均完成治疗,未出现严重毒副作用。治疗组患者治疗6个月后FibroScan肝硬度值（ Stiffness值）较治疗前明显降低,差异有显著性意义（ P＜0.05）。而对照组患者,均未见明显变化。两组患者治疗6个月后的肝功能及HBV DNA都有显著改善（P＜0.05）,且治疗组较对照组改善得更为明显（P＜0.05）。结论：核苷类似物联合安络化纤丸治疗乙型肝炎肝硬化有良好的抗纤维化效果,并能改善肝功能,疗效优于核苷类似物联合护肝片。     

复方甘草酸苷联合复方鳖甲软肝片治疗代偿性乙型肝炎肝硬化的疗效观察

目的观察复方甘草酸苷联合复方鳖甲软肝片对代偿性乙型肝炎肝硬化的疗效。方法86例代偿性肝硬化患者,随机分为治疗组44例,对照组42例。对照组给予复方甘草酸苷片（美能片剂）口服,每次2片,3／d,疗程6个月;在此基础上,治疗组加用复方鳖甲软肝片,口服,每次4片,3／d,疗程6个月。对照观察2组肝功能、肝纤维化指标变化。结果治疗组疗效明显优于对照组,2组差异有统计学意义。结论复方甘草酸苷联合复方鳖甲软肝片治疗肝纤维化疗效明显优于单用复方甘草酸苷组,说明两者合用具有较强的抗肝纤维化、抗肝硬化作用,具有协同作用。     

安络化纤丸对36例慢性乙肝患者甲襞微循环的影响

我们观察了 36例慢性乙型肝炎 (下称乙肝 )患者口服安络化纤丸前后甲襞微循环的变化 ,现将结果报告如下。临床资料 :将同期收治的 6 6例乙肝患者随机分为两组 ,治疗组男 2 4例 ,女 12例 ,年龄 2 2～ 5 2岁 ;对照组男 18例 ,女 12例 ,年龄 2 0～ 5 4岁。两组年龄、性别无显著差异 (P>0 .0 5 )。所有患者均符合 1995年全国传染病与寄生虫病会议修订的慢性乙型肝炎诊断标准。方法 :治疗组口服安络化纤丸 ,6 g/次 ,3次 / d。对照组口服西利宾胺 ,2片 /次 ,3次 / d。两组均给予对症治疗 ,用药过程中避免使用影响微循环的药物以及抗肝纤维化的药…     

恩替卡韦联合大黄蟅虫丸治疗慢性乙型肝炎早期肝硬化26例

[目的]观察恩替卡韦联合大黄蟅虫丸治疗慢性乙型肝炎早期肝硬化的临床疗效。[方法]将52例慢性乙型肝炎早期肝硬化患者随机分为对照组和观察组,每组26例。对照组予恩替卡韦分散片,0.5mg/次,1次/d,口服治疗,观察组在对照组治疗基础上加服大黄蟅虫丸,2丸/次,2次/d。2组均连续治疗24周,比较2组临床疗效、肝功能和肝纤维化指标变化。[结果]观察组临床疗效明显优于对照组,观察组肝功能和肝纤维化指标改善较对照组更明显(P0.01)。[结论]恩替卡韦联合大黄蟅虫丸治疗慢性乙型肝炎早期肝硬化疗效显著。     

安络化纤丸治疗中晚期肝炎肝硬化70例临床观察

目的:观察肝炎肝硬化患者应用安络化纤丸治疗后临床症状、体征、肝功能、血清肝纤维化指标的恢复情况和肝脏脾脏影象学改变.方法:138名中晚期肝硬化患者分为两组,治疗组70例患者口服安络化纤丸,6g/次,3次/d;对照组68例接受丹参片治疗,3片/次,3次/d.两组疗程均为6个月.结果:安络化纤丸治疗后血清透明质酸酶(HA)、层粘蛋白(LN)和Ⅲ型前胶原(PC-Ⅲ)平均水平下降十分显著,HA尤为显著,HA尤为突出;肝脏影象学检查有显著改善.结论:安络化纤丸有较好的抗肝硬化效果.     

Treatment of cachexia with ghrelin in patients with COPD

STUDY OBJECTIVES: Ghrelin is a novel growth hormone (GH)-releasing peptide that also induces a positive energy balance by decreasing fat utility and stimulating feeding through GH-independent mechanisms. We investigated whether ghrelin improves cachexia and functional capacity in patients with COPD. METHODS: This is an open-label pilot study. Human ghrelin (2 microg/kg bid) was IV administered to seven cachectic patients with COPD for 3 weeks. Food intake, body composition, muscle strength, exercise capacity, pulmonary function, and sympathetic nerve activity were examined before and after ghrelin therapy. RESULTS: A single administration of ghrelin markedly increased serum GH (21-fold). Three-week treatment with ghrelin resulted in a significant increase in mean (+/- SEM) body weight (49.3 +/- 3.6 to 50.3 +/- 3.8 kg; p < 0.05). Food intake was significantly increased during ghrelin therapy. Ghrelin increased lean body mass and peripheral and respiratory muscle strength. Ghrelin significantly increased Karnofsky performance status score and the distance walked in 6 min (370 +/- 30 to 432 +/- 35 m; p < 0.05), although it did not significantly alter pulmonary function. Ghrelin attenuated the exaggerated sympathetic nerve activity, as indicated by a marked decrease in plasma norepinephrine level (889 +/- 123 to 597 +/- 116 pg/mL; p < 0.05). CONCLUSIONS: These preliminary results suggest that repeated administration of ghrelin improves body composition, muscle wasting, functional capacity, and sympathetic augmentation in cachectic patients with COPD.     

辛伐他汀对血脂异常人群缺血性脑卒中的预防

目的研究辛伐他汀对血脂异常人群缺血性脑卒中的预防作用。方法将2853例血脂异常人群分为预防组(693例)和对照组(2160例),预防组给予辛伐他汀20mg/d,睡前口服。分析2组血脂变化、心脑血管事件、脑卒中等差异。结果预防组受试者糖尿病患病率比对照组高,预防组随访率98．7%,对照组随访率96．2%。预防组低密度脂蛋白胆固醇较对照组低[(2．54±1．01)mmol/L vs(4．12±1．29)mmol/L,P＜0．05],5年生存率高(94．13% vs 83．47%,P＜0．01),缺血性脑卒中和心脑血管事件发生率低。2组死亡的主要原因是:心脑血管疾病、肿瘤和感染。吸烟、高血压、肥胖和糖尿病是脑卒中和心脑血管事件的高危因素。结论辛伐他汀能有效降低血脂异常人群的心脑血管事件。     

Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension

This randomised, double-blind study was designed to investigate the efficacy of a once-daily (OD) combination of the AT(1) receptor blocker, eprosartan 600 mg, and the thiazide diuretic, hydrochlorothiazide (HCTZ) 12.5 mg, in patients with mild to moderate hypertension (sitting diastolic blood pressure (sitDBP) > or =98 mm Hg and < or =114 mm Hg) not adequately controlled with eprosartan 600 mg OD. A total of 494 patients entered the open-label monotherapy run-in phase, which consisted of eprosartan 600 mg OD for 3 weeks. Patients who responded to monotherapy were not eligible to enter the randomised phase of the study and were withdrawn. The remaining 309 patients were then randomised to either eprosartan 600 mg plus HCTZ 12.5 mg OD or to continue on eprosartan 600 mg OD. In the eprosartan plus HCTZ combination group, both sitDBP and sitting systolic blood pressure (sitSBP) were significantly reduced compared with the eprosartan monotherapy group. In addition, the response rate was higher in the combination group compared with the monotherapy group. There were no significant effects on reduction of sitDBP due to gender, prior use of antihypertensives or baseline severity of hypertension. The tolerability profile for the combination group was similar to that for the monotherapy group. Headache was the most frequent adverse event in both treatment groups. The majority of adverse events were mild to moderate in intensity. In this study of patients who were unresponsive to eprosartan monotherapy for 3 weeks, a combination product of eprosartan 600 mg and HCTZ 12.5 mg was shown to be an effective and well tolerated treatment.